OncoImmunology, Год журнала: 2024, Номер 14(1)

Опубликована: Дек. 26, 2024

Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor cells (CAR-T), there is still an important number of patients experiencing refractory/relapsed (R/R) disease. Approaches to avoid tumor-intrinsic mechanisms resistance immune pressure-mediated downmodulation, are being broadly investigated. These strategies include BCMA/CD19 dual-targeting therapies, which may be particular interest with lymphoma multiple myeloma, where a specific double-positive immature subpopulation commonly associated poor prognosis response current treatments. In fact, several clinical trials targeting both antigens through different currently underway. Here, based on the previously validated STAb (in situ secretion cell-redirecting bispecific antibodies) concept, we used two engineering (pool co-transduction) generate dual-targeted STAb-T simultaneously secreting TCE CD19 that outperformed single-targeted vitro models. promising results encourage further preclinical testing dual R/R B-cell malignancies.

Язык: Английский